You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
Help Center
uSMARTPORT
Download
About
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsInformation about Individual Stocks

Jacobio Pharmaceuticals Group Co., Ltd. (01167)

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor

Business Collaboration
Register now

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
Email: cs@usmart.hk
WhatsApp: +852 5989 2641
uSMART-Facebook-Page
Headquarters
Investment Banking
uSMART Network
uSmart Securities Limited is a corporation licensed by the Hong Kong Securities and Futures Commission (CE No.: BJA907) and is authorised to carry on Type 1 (Dealing in Securities), Type 2 (Dealing in Futures Contracts), Type 4 (Advising on Securities), Type 5 (Advising on Futures Contracts), Type 6 (Advising on Corporate Finance) and Type 9 (Asset Management) regulated activities.